Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs Uses Rubicon's Single-Cell Amplification Tech in New WGA Kit


New England Biolabs said this week that it has licensed single-cell amplification technology from Rubicon Genomics that it will market in a new kit for whole-genome amplification of single cells and low quantities of DNA.

The Single Cell Whole Genome Amplification kit is NEB's first product for the single-cell amplification market. The company said it expects the new kit to find use in "numerous research applications, including cancer studies."

Jim Koziarz, President and CEO of Rubicon, said in a statement that the company's single-cell amplification technology "has already been widely adopted in the in vitro fertilization market, and we are excited at the prospects this product has in research applications."

According to NEB, the Single Cell WGA kit can amplify total DNA from single cells or their DNA equivalent about 1 million-fold to produce 2 mg to 5 mg of amplified DNA in under three hours. It can also be used in situations "where the low input amount is uncertain as it works well over a range of inputs up to thousands of cells or several [nanograms of] DNA to achieve this final yield of amplified DNA."

The company said that the kit has been used successfully for single blastomeres, polar bodies, trophoblasts, amniocytes, and cultured cells and achieves a 95 percent amplification success rate.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.